RHOEN-KLINIKUM AG (RHK.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:RHK - DE0007042301 - Common Stock
12.8 EUR
+0.3 (+2.4%)
Taking everything into account, RHK scores 5 out of 10 in our fundamental rating. RHK was compared to 29 industry peers in the Health Care Providers & Services industry. RHK has an excellent financial health rating, but there are some minor concerns on its profitability. While showing a medium growth rate, RHK is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
RHK had positive earnings in the past year.
In the past year RHK had a positive cash flow from operations.
In the past 5 years RHK has always been profitable.
In the past 5 years RHK always reported a positive cash flow from operatings.
1.2 Ratios
With a Return On Assets value of 2.02%, RHK is not doing good in the industry: 62.07% of the companies in the same industry are doing better.
The Return On Equity of RHK (2.90%) is worse than 72.41% of its industry peers.
With a Return On Invested Capital value of 2.67%, RHK is not doing good in the industry: 72.41% of the companies in the same industry are doing better.
RHK had an Average Return On Invested Capital over the past 3 years of 2.34%. This is below the industry average of 6.67%.
The 3 year average ROIC (2.34%) for RHK is below the current ROIC(2.67%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.02% | ||
| ROE | 2.9% | ||
| ROIC | 2.67% |
ROA(3y)2%
ROA(5y)1.56%
ROE(3y)2.83%
ROE(5y)2.2%
ROIC(3y)2.34%
ROIC(5y)2.01%
1.3 Margins
Looking at the Profit Margin, with a value of 2.28%, RHK is in line with its industry, outperforming 41.38% of the companies in the same industry.
In the last couple of years the Profit Margin of RHK has declined.
RHK's Operating Margin of 2.86% is on the low side compared to the rest of the industry. RHK is outperformed by 65.52% of its industry peers.
RHK's Operating Margin has declined in the last couple of years.
RHK has a Gross Margin of 66.81%. This is in the better half of the industry: RHK outperforms 72.41% of its industry peers.
RHK's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.86% | ||
| PM (TTM) | 2.28% | ||
| GM | 66.81% |
OM growth 3Y11.39%
OM growth 5Y-7.03%
PM growth 3Y10.42%
PM growth 5Y-3.92%
GM growth 3Y-1.4%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), RHK is destroying value.
RHK has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, RHK has about the same amount of shares outstanding.
RHK has a better debt/assets ratio than last year.
2.2 Solvency
RHK has an Altman-Z score of 3.04. This indicates that RHK is financially healthy and has little risk of bankruptcy at the moment.
RHK has a better Altman-Z score (3.04) than 86.21% of its industry peers.
RHK has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.09, RHK belongs to the top of the industry, outperforming 96.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.04 |
ROIC/WACC0.42
WACC6.44%
2.3 Liquidity
A Current Ratio of 2.28 indicates that RHK has no problem at all paying its short term obligations.
RHK has a Current ratio of 2.28. This is amongst the best in the industry. RHK outperforms 96.55% of its industry peers.
RHK has a Quick Ratio of 2.19. This indicates that RHK is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 2.19, RHK belongs to the best of the industry, outperforming 96.55% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.19 |
3. Growth
3.1 Past
The earnings per share for RHK have decreased strongly by -15.41% in the last year.
The Earnings Per Share has been growing slightly by 0.03% on average over the past years.
The Revenue has grown by 9.10% in the past year. This is quite good.
The Revenue has been growing slightly by 4.12% on average over the past years.
EPS 1Y (TTM)-15.41%
EPS 3Y15.28%
EPS 5Y0.03%
EPS Q2Q%3.33%
Revenue 1Y (TTM)9.1%
Revenue growth 3Y4.41%
Revenue growth 5Y4.12%
Sales Q2Q%8.37%
3.2 Future
The Earnings Per Share is expected to grow by 11.89% on average over the next years. This is quite good.
RHK is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.24% yearly.
EPS Next Y4.3%
EPS Next 2Y10.47%
EPS Next 3Y11.09%
EPS Next 5Y11.89%
Revenue Next Year6.74%
Revenue Next 2Y5.36%
Revenue Next 3Y6.5%
Revenue Next 5Y6.24%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 22.46, the valuation of RHK can be described as rather expensive.
Based on the Price/Earnings ratio, RHK is valued a bit more expensive than the industry average as 65.52% of the companies are valued more cheaply.
Compared to an average S&P500 Price/Earnings ratio of 26.34, RHK is valued at the same level.
RHK is valuated correctly with a Price/Forward Earnings ratio of 16.75.
Compared to the rest of the industry, the Price/Forward Earnings ratio of RHK is on the same level as its industry peers.
The average S&P500 Price/Forward Earnings ratio is at 23.56. RHK is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.46 | ||
| Fwd PE | 16.75 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, RHK is valued cheaper than 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 0.14 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates RHK does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)5.22
PEG (5Y)660.35
EPS Next 2Y10.47%
EPS Next 3Y11.09%
5. Dividend
5.1 Amount
With a yearly dividend of 0.81%, RHK is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 2.40, RHK has a dividend in line with its industry peers.
With a Dividend Yield of 0.81, RHK pays less dividend than the S&P500 average, which is at 2.31.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.81% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
RHK pays out 17.78% of its income as dividend. This is a sustainable payout ratio.
DP17.78%
EPS Next 2Y10.47%
EPS Next 3Y11.09%
FRA:RHK (12/8/2025, 12:54:12 PM)
12.8
+0.3 (+2.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners0.55%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap857.09M
Revenue(TTM)1.69B
Net Income(TTM)37.68M
Analysts74.29
Price Target14.45 (12.89%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.81% |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP17.78%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-4.43%
EPS NY rev (3m)-4.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.72%
Revenue NY rev (3m)0.72%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.46 | ||
| Fwd PE | 16.75 | ||
| P/S | 0.52 | ||
| P/FCF | N/A | ||
| P/OCF | 13.89 | ||
| P/B | 0.66 | ||
| P/tB | 0.76 | ||
| EV/EBITDA | 0.14 |
EPS(TTM)0.57
EY4.45%
EPS(NY)0.76
Fwd EY5.97%
FCF(TTM)-0.12
FCFYN/A
OCF(TTM)0.92
OCFY7.2%
SpS24.7
BVpS19.41
TBVpS16.81
PEG (NY)5.22
PEG (5Y)660.35
Graham Number15.78
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.02% | ||
| ROE | 2.9% | ||
| ROCE | 3.25% | ||
| ROIC | 2.67% | ||
| ROICexc | 4.45% | ||
| ROICexgc | 5.55% | ||
| OM | 2.86% | ||
| PM (TTM) | 2.28% | ||
| GM | 66.81% | ||
| FCFM | N/A |
ROA(3y)2%
ROA(5y)1.56%
ROE(3y)2.83%
ROE(5y)2.2%
ROIC(3y)2.34%
ROIC(5y)2.01%
ROICexc(3y)3.1%
ROICexc(5y)2.62%
ROICexgc(3y)3.7%
ROICexgc(5y)3.13%
ROCE(3y)2.85%
ROCE(5y)2.44%
ROICexgc growth 3Y17.7%
ROICexgc growth 5Y-1.56%
ROICexc growth 3Y17.75%
ROICexc growth 5Y-1.75%
OM growth 3Y11.39%
OM growth 5Y-7.03%
PM growth 3Y10.42%
PM growth 5Y-3.92%
GM growth 3Y-1.4%
GM growth 5Y-0.67%
F-Score6
Asset Turnover0.89
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 1.07 | ||
| Cap/Depr | 112.99% | ||
| Cap/Sales | 4.21% | ||
| Interest Coverage | 14.78 | ||
| Cash Conversion | 56.66% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.28 | ||
| Quick Ratio | 2.19 | ||
| Altman-Z | 3.04 |
F-Score6
WACC6.44%
ROIC/WACC0.42
Cap/Depr(3y)97.27%
Cap/Depr(5y)108.32%
Cap/Sales(3y)4.24%
Cap/Sales(5y)5.08%
Profit Quality(3y)86.55%
Profit Quality(5y)290.53%
High Growth Momentum
Growth
EPS 1Y (TTM)-15.41%
EPS 3Y15.28%
EPS 5Y0.03%
EPS Q2Q%3.33%
EPS Next Y4.3%
EPS Next 2Y10.47%
EPS Next 3Y11.09%
EPS Next 5Y11.89%
Revenue 1Y (TTM)9.1%
Revenue growth 3Y4.41%
Revenue growth 5Y4.12%
Sales Q2Q%8.37%
Revenue Next Year6.74%
Revenue Next 2Y5.36%
Revenue Next 3Y6.5%
Revenue Next 5Y6.24%
EBIT growth 1Y2.05%
EBIT growth 3Y16.29%
EBIT growth 5Y-3.2%
EBIT Next Year147.27%
EBIT Next 3Y44.19%
EBIT Next 5Y28.34%
FCF growth 1Y26.17%
FCF growth 3Y42.66%
FCF growth 5YN/A
OCF growth 1Y42.49%
OCF growth 3Y9.38%
OCF growth 5Y21.95%
RHOEN-KLINIKUM AG / RHK.DE FAQ
Can you provide the ChartMill fundamental rating for RHOEN-KLINIKUM AG?
ChartMill assigns a fundamental rating of 5 / 10 to RHK.DE.
What is the valuation status for RHK stock?
ChartMill assigns a valuation rating of 2 / 10 to RHOEN-KLINIKUM AG (RHK.DE). This can be considered as Overvalued.
What is the profitability of RHK stock?
RHOEN-KLINIKUM AG (RHK.DE) has a profitability rating of 4 / 10.
What is the valuation of RHOEN-KLINIKUM AG based on its PE and PB ratios?
The Price/Earnings (PE) ratio for RHOEN-KLINIKUM AG (RHK.DE) is 22.46 and the Price/Book (PB) ratio is 0.66.
Can you provide the expected EPS growth for RHK stock?
The Earnings per Share (EPS) of RHOEN-KLINIKUM AG (RHK.DE) is expected to grow by 4.3% in the next year.